Close Menu
NEW YORK – Genomica, a Spanish molecular diagnostics firm owned by the PharmaMar Group, has obtained CE marking for its COVID-19 (SARS-CoV2) coronavirus diagnostic kits.
 
The company has developed two kits: qCOVID-19, which uses real-time PCR, and CLART COVID-19, which uses the company's CLART technology, a low-density microarray-based platform that allows the detection of multiple targets in a single test.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.